All In Biotech

Drug Trial Radar · NCT07465289

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Mar 17, 2031

Study completion Mar 17, 2031

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.

Conditions

  • Ocular Myasthenia Gravis

Interventions

  • RozanolixizumabDrug

    Rozanolixizumab will be administered by subcutaneous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: Up to 2 years
  2. Incidence of treatment-emergent serious adverse events (TESAEs)Time frame: Up to 2 years
  3. Incidence of TEAEs leading to permanent withdrawal of study treatmentTime frame: Up to 2 years

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Mg0039 10104

    Scottsdale, Arizona · Recruiting

  • Mg0039 10103

    Columbus, Ohio · Recruiting

  • Mg0039 31901

    Beijing, China · Recruiting

  • Mg0039 31912

    Beijing, China · Recruiting

  • Mg0039 31908

    Chongqing, China · Recruiting

  • Mg0039 31907

    Nanchang, China · Recruiting

  • Mg0039 31902

    Suzhou, China · Recruiting

  • Mg0039 20301

    Nice, France · Recruiting

  • Mg0039 21403

    Sarajishvili, Georgia · Recruiting

  • Mg0039 21402

    Tbilisi, Georgia · Recruiting

  • Mg0039 31802

    Kobe, Japan · Recruiting

  • Mg0039 31804

    Minatoku, Japan · Recruiting

  • Mg0039 31805

    Sendai, Japan · Recruiting

  • Mg0039 21206

    Lublin, Poland · Recruiting

  • Mg0039 20604

    Barcelona, Spain · Recruiting

  • Mg0039 20611

    Madrid, Spain · Recruiting

  • Mg0039 20606

    Málaga, Spain · Recruiting

  • Mg0039 20602

    Murcia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.